Graham Capital Management L.P. Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Graham Capital Management L.P. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 18,886 shares of the biopharmaceutical company's stock, valued at approximately $1,744,000.

Several other large investors have also recently bought and sold shares of GILD. FMR LLC grew its holdings in Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. Wellington Management Group LLP boosted its holdings in Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after buying an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after buying an additional 749,047 shares in the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences during the 4th quarter worth $1,789,254,000. Finally, Northern Trust Corp grew its holdings in shares of Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after acquiring an additional 2,458,954 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 22,929 shares of company stock worth $2,644,895. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $1.96 during trading on Thursday, reaching $100.34. The company had a trading volume of 9,416,542 shares, compared to its average volume of 7,654,276. The company has a market capitalization of $124.94 billion, a PE ratio of 271.19, a PEG ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm's 50 day simple moving average is $106.33 and its two-hundred day simple moving average is $99.50. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the previous year, the company earned ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 3.15%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. Oppenheimer decreased their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Bank of America raised their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group increased their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.